Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

First-in-Class Selective Nurr1:RXRα Modulators with a Unique Biophysical Mechanism driving multi-pathway Disease Modification in Parkinson’s Disease.

Ziel

NURRAPEUTICS develops first-in-class, selective Nurr1:RXRα small-molecule modulators that act through a unique biophysical mechanism driving multi-pathway neuroprotection, anti-inflammatory activity, and proteostasis restoration. Nurr1 is a well-established regulator of neuronal survival and homeostasis, and current Parkinson’s treatments remain purely symptomatic with no impact on progression. By selectively modulating Nurr1—rather than broadly activating RXR—our compounds unlock a differentiated, mechanism-based approach to multi-pathway disease modification in Parkinson’s disease.
Using a proprietary Mechanism–Structure–Function approach, SyNoesis has generated a portfolio of brain-penetrant, orally active candidate modulators supported by orthogonal biophysical assays and robust in-vivo efficacy across multiple PD models. These candidates show favorable profiling in potency, selectivity, ADMET and preliminary safety. Two new composition-of-matter patent families covering the Gen-3/4 chemotypes are fully drafted and ready for filing upon project invitation for funding.
During the 24-month EIC Pre-Accelerator, NURRAPEUTICS will progress from TRL 4 to TRL 6, completing CMC development, PK/PD integration, and two-species GLP toxicology to produce a Quality-Assurance-approved IMPD/CTA dossier. This will enable a Phase-I-ready asset within 12 months post-project. In parallel, we will reach IRL 8 by finalizing the business plan, investor data room and partnering strategy.
The outcome of NURRAPEUTICS is a first-in-class, mechanism-driven therapeutic approach with strong preclinical evidence for disease-modifying potential in Parkinson’s disease, developed through a capital-efficient EU pathway and positioned for Accelerator Fast-Track readiness.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-CSA - HORIZON Coordination and Support Actions

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-WIDERA-2025-02

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

SYNOESIS THERAPEUTICS LTD
Netto-EU-Beitrag
€ 492 450,00
Adresse
77 STROVOLOU STREET
2018 NICOSIA
Zypern
KMU
Ja
Region
Κύπρος Κύπρος Κύπρος
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten